Sickle cell trait evolved as protection against malaria, especially in tropical regions. Its discovery advanced understanding ...

Although sickle cell disease (SCD) is not as widespread in the Philippines compared to other populations, it is still worth ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...